T1	Person 55 60	NSCLC
T2	Person 27 53	non-small cell lung cancer
T3	Person 77 88	RAS-pathway
T4	Person 139 144	GATA2
T5	Person 235 260	receptor tyrosine kinases
T6	Person 262 265	RTK
T7	Person 361 367	mutant
T8	Person 348 357	wild-type
T9	Person 395 399	RNAi
T10	Person 472 488	decrease in KRAS
T11	Person 576 588	KRAS-pathway
T12	Person 603 606	PC9
T13	Person 614 625	EGFR mutant
T14	Person 741 761	proteasome machinery
T15	Person 763 777	IL-1-signaling
T16	Person 783 796	Rho-signaling
T17	Person 845 850	TRAF6
T18	Person 872 880	ablation
T19	Person 854 859	mouse
T20	Person 1195 1198	Rho
T21	Person 1221 1232	therapeutic
T22	Person 1283 1293	bortezomib
T23	Person 1298 1305	fasudil
T24	Person 1252 1271	clinically approved
